Mesenchymal Stem Cell Therapy in Severe COVID-19 in a Young Male Healthcare Worker with Tetralogy of Fallot

Authors : Recep Civan Yüksel, Esma Eren, Ayşegül Ulu Kiliç, Ilhami Çelik

Pages : 26-30

View : 20 | Download : 7

Publication Date : 2022-04-01

Article Type : Other

Abstract :Background: A novel type of coronavirus (SARS- CoV -2), which cause severe acute respiratory syndrome, was first identified in Wuhan, China at the end of December 2019 and the disease rapidly spread worldwide. COVID-19 may be characterized by a range of symptoms; mild illness to severe pneumoniae. Cardiovascular diseases increase severity and mortality in COVID-19 patients. Tetralogy of Fallot (ToF) is the most common cyanotic congenital heart disease. Case presentation: Present case is an adult COVID-19 patient with a history of ToF, who is a healthcare worker. High Flow Nasal Oxygen (HFNO) was used due to respiratory distress. In addition, Mesenchymal Stem Cells (MSCs) were applied while the disease was in critical process. Clinical and laboratory improvement was observed in the patient from the second day of treatment of MSCs. Conclusions: The young healthcare worker with a history of ToF needed critical care due to COVID-19. Response to the antiviral treatments given to the patient could not be obtained. HFNO and MSCs were used in the treatment of the patient. Clinical and laboratory improvement was observed in the patient from the second day of treatment of MSCs.
Keywords : Mesenchymal Stem Cell, COVID19, HFNO